P1018: UPDATED RESULTS FROM MANIFEST ARM 2: EFFICACY AND SAFETY OF PELABRESIB (CPI-0610) AS ADD-ON TO RUXOLITINIB IN MYELOFIBROSIS

• Marina Kremyanskaya,
• Claire Harrison,
• Prithviraj Bose,
• Vikas Gupta,
• Raajit K Rampal,
• Jonathan Lambert,
• Moshe Talpaz,
• Alessandro Vannucchi,
• Andrew Kuykendall,
• Jean-Jacques Kiladjian,
• Srdan Verstovsek,
• Ruben Mesa,
• Gozde Colak,
• Sandra Klein,
• Carmelita Alvero,
• John Mascarenhas

Affiliations

Marina Kremyanskaya

1 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, United States

Claire Harrison

2 Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom

Prithviraj Bose

3 MD Anderson Cancer Center, Houston, United States

Vikas Gupta

4 Princess Margaret Hospital, Medical Oncology and Hematology, Toronto, Canada

Raajit K Rampal

5 Memorial Sloan Kettering Cancer Center, Leukemia Service, New York, United States

Jonathan Lambert

6 University College London Hospitals, NHS Foundation Trust, London, United Kingdom

Moshe Talpaz

7 University of Michigan, Michigan Medicine, Michigan, United States

Alessandro Vannucchi

8 Azienda Ospedaliero Universitaria Careggi, University of Florence, Florence, Italy

Andrew Kuykendall

9 H. Lee Moffitt Cancer Center, Department of Malignant Hematology, Tampa, United States

Jean-Jacques Kiladjian

10 Université Paris Cité and Hopital Saint-Louis, AP-HP, Clinical Investigation Center, Paris, France

Srdan Verstovsek

11 Leukemia Department, The University of Texas MD Anderson Cancer Center, Houston, United States

Ruben Mesa

12 Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, United States

Gozde Colak

13 Constellation Pharmaceuticals, Inc., a MorphoSys Company, Boston, United States

Sandra Klein

13 Constellation Pharmaceuticals, Inc., a MorphoSys Company, Boston, United States

Carmelita Alvero

14 MorphoSys US, Inc., Boston, United States

John Mascarenhas

1 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, United States